Africa: Malaria Vaccine Candidate Reduces Disease Over 18 Months of Follow-Up in Late-Stage Study

[PATH]Durban, South Africa -Results from a large-scale Phase III trial, presented today in Durban at the Multilateral Initiative on Malaria Pan African Conference, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination. Based on these data, GSK now intends to submit, in 2014, a regulatory application to the European Medicines Agency (EMA). The World Health Organization (WHO) has indicated that a policy recommendat

Powered by WPeMatico

This entry was posted in Science. Bookmark the permalink.

Comments are closed.